Trial Profile
Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2016
Price :
$35
*
At a glance
- Drugs Veldoreotide (Primary) ; Octreotide
- Indications Acromegaly
- Focus Adverse reactions
- Sponsors Aspireo Pharmaceuticals
- 31 May 2016 According to a Strongbridge Biopharma media release, data from this study were presented at the 18th European Congress of Endocrinology.
- 30 Apr 2014 Planned number of patients changed to 48.
- 30 Apr 2014 New trial record